TW201006829A - Method of treating cancer using a cMET and AXL inhibitor and an erbB inhibitor - Google Patents

Method of treating cancer using a cMET and AXL inhibitor and an erbB inhibitor Download PDF

Info

Publication number
TW201006829A
TW201006829A TW098114669A TW98114669A TW201006829A TW 201006829 A TW201006829 A TW 201006829A TW 098114669 A TW098114669 A TW 098114669A TW 98114669 A TW98114669 A TW 98114669A TW 201006829 A TW201006829 A TW 201006829A
Authority
TW
Taiwan
Prior art keywords
compound
cmet
erbb
cancer
hgf
Prior art date
Application number
TW098114669A
Other languages
English (en)
Chinese (zh)
Inventor
Tona M Gilmer
James G Greger Jr
Li Liu
Hong Shi
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41257222&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW201006829(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of TW201006829A publication Critical patent/TW201006829A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW098114669A 2008-05-05 2009-05-04 Method of treating cancer using a cMET and AXL inhibitor and an erbB inhibitor TW201006829A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5032208P 2008-05-05 2008-05-05

Publications (1)

Publication Number Publication Date
TW201006829A true TW201006829A (en) 2010-02-16

Family

ID=41257222

Family Applications (1)

Application Number Title Priority Date Filing Date
TW098114669A TW201006829A (en) 2008-05-05 2009-05-04 Method of treating cancer using a cMET and AXL inhibitor and an erbB inhibitor

Country Status (19)

Country Link
US (3) US20090274693A1 (cg-RX-API-DMAC7.html)
EP (1) EP2274304A4 (cg-RX-API-DMAC7.html)
JP (1) JP2011519941A (cg-RX-API-DMAC7.html)
KR (1) KR20110004462A (cg-RX-API-DMAC7.html)
CN (1) CN102083824A (cg-RX-API-DMAC7.html)
AR (1) AR071631A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009244453B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0912582A2 (cg-RX-API-DMAC7.html)
CA (1) CA2723699A1 (cg-RX-API-DMAC7.html)
CL (1) CL2009001063A1 (cg-RX-API-DMAC7.html)
EA (1) EA020779B1 (cg-RX-API-DMAC7.html)
IL (1) IL209057A0 (cg-RX-API-DMAC7.html)
MX (1) MX2010012101A (cg-RX-API-DMAC7.html)
PE (1) PE20091832A1 (cg-RX-API-DMAC7.html)
SG (1) SG190623A1 (cg-RX-API-DMAC7.html)
TW (1) TW201006829A (cg-RX-API-DMAC7.html)
UY (1) UY31800A (cg-RX-API-DMAC7.html)
WO (1) WO2009137429A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201007722B (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI478933B (zh) * 2011-01-28 2015-04-01 Konruns Pharmaceutical Co Ltd A quinoline compound containing a phosphorus substituent and a process for preparing the same, and a pharmaceutical composition containing the same and a use thereof
US9522902B2 (en) 2011-11-14 2016-12-20 Ignyta, Inc. Uracil derivatives as AXL and c-MET kinase inhibitors

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2629244C (en) 2005-11-11 2014-08-05 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
EP2387563B2 (en) 2009-01-16 2022-04-27 Exelixis, Inc. Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quinolin-4-yl]oxy}phenyl-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
NZ594339A (en) 2009-03-25 2013-06-28 Genentech Inc Anti-fgfr3 antibodies and methods using same
WO2011003853A2 (en) 2009-07-06 2011-01-13 Boehringer Ingelheim International Gmbh Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
AR077595A1 (es) * 2009-07-27 2011-09-07 Genentech Inc Tratamientos de combinacion
WO2011014872A2 (en) * 2009-07-31 2011-02-03 The Johns Hopkins University Compositions and methods for diagnosing, treating or preventing neoplasias
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
PL2719708T3 (pl) * 2009-11-13 2018-04-30 Daiichi Sankyo Europe Gmbh Materiał i sposoby leczenia lub zapobiegania chorobom związanym z HER-3
WO2012009722A1 (en) 2010-07-16 2012-01-19 Exelixis, Inc. C-met modulator pharmaceutical compositions
MY162825A (en) 2010-08-20 2017-07-31 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
FI2621481T4 (fi) 2010-09-27 2023-01-13 Met- ja vegf-kaksoisestäjiä kastraatioresistentin eturauhassyövän ja osteoblastisten luun etäispesäkkeiden hoitamiseen
SG10201510086VA (en) * 2010-12-23 2016-01-28 Nestec Sa Drug selection for malignant cancer therapy using antibody-based arrays
CN102532109B (zh) * 2010-12-27 2015-05-13 浙江海正药业股份有限公司 一种拉帕替尼及其盐的合成方法
EP4019498A1 (en) 2011-02-10 2022-06-29 Exelixis, Inc. Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
US20140179736A1 (en) * 2011-05-02 2014-06-26 Exelixis, Inc. Method of Treating Cancer and Bone Cancer Pain
MX351133B (es) 2011-09-22 2017-10-03 Exelixis Inc Metodo para tratar osteoporosis.
AR088483A1 (es) 2011-10-20 2014-06-11 Exelixis Inc Proceso para preparar derivados de quinolina
UY34487A (es) * 2011-12-05 2013-07-31 Novartis Ag Anticuerpos para receptor de factor de crecimiento epidérmico 3(her3)
TWI594986B (zh) 2011-12-28 2017-08-11 Taiho Pharmaceutical Co Ltd Antineoplastic agent effect enhancer
JP6006241B2 (ja) 2012-01-31 2016-10-12 第一三共株式会社 ピリドン誘導体
EP2844254A1 (en) 2012-05-02 2015-03-11 Exelixis, Inc. A dual met - vegf modulator for treating osteolytic bone metastases
CN103664879A (zh) * 2012-09-17 2014-03-26 杨育新 一类治疗创伤性脑损伤疾病的化合物及其用途
CN103705521A (zh) * 2012-09-28 2014-04-09 韩冰 一类治疗脑梗塞的化合物及其用途
WO2014093750A1 (en) * 2012-12-14 2014-06-19 Glaxosmithkline Llc Method of administration and treatment
MX366003B (es) 2013-03-15 2019-06-24 Exelixis Inc Metabolitos de n-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n' -(4-fluorofenil)ciclopropan-1,1-dicarboxamida.
KR102060540B1 (ko) 2013-04-03 2019-12-31 삼성전자주식회사 항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물
ES2927651T3 (es) 2013-04-04 2022-11-10 Exelixis Inc Forma de dosificación de cabozantinib y uso en el tratamiento del cáncer
TWI649308B (zh) 2013-07-24 2019-02-01 小野藥品工業股份有限公司 喹啉衍生物
CA2926262C (en) 2013-10-14 2025-06-17 Janssen Biotech, Inc. CYSTEINE MODIFIED TYPE III FIBRONECTIN DOMAIN BINDING MOLECULES (FN3)
SG11201606413RA (en) * 2014-02-04 2016-09-29 Astellas Pharma Inc Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient
EP3738952A1 (en) 2014-02-14 2020-11-18 Exelixis, Inc. Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
JP6666849B2 (ja) 2014-03-17 2020-03-18 エグゼリクシス， インコーポレイテッド カボザンチニブ製剤の投与
NZ725361A (en) * 2014-04-03 2022-09-30 Merck Patent Gmbh Combinations of cancer therapeutics
KR102223502B1 (ko) 2014-05-09 2021-03-05 삼성전자주식회사 항 c-Met/항 EGFR/항 Her3 다중 특이 항체 및 이의 이용
TWI723572B (zh) 2014-07-07 2021-04-01 日商第一三共股份有限公司 具有四氫吡喃基甲基之吡啶酮衍生物及其用途
EA033834B1 (ru) 2014-07-31 2019-11-29 Exelixis Inc Способ получения кабозантиниба, меченного фтором-18, и его аналогов
MA40457A (fr) 2014-08-05 2017-06-14 Exelixis Inc Combinaison de médicaments pour traiter le myélome multiple
US10208034B2 (en) 2014-12-25 2019-02-19 Ono Pharmaceutical Co., Ltd. Quinoline derivative
FR3039401B1 (fr) * 2015-07-31 2018-07-13 Les Laboratoires Servier Nouvelle association entre le 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione et un inhibiteur de la tyr kinase du egfr
CN106467541B (zh) * 2015-08-18 2019-04-05 暨南大学 取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用
US11141413B2 (en) 2016-04-15 2021-10-12 Exelixis, Inc. Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
EP3471750A4 (en) 2016-06-21 2020-02-26 Janssen Biotech, Inc. Cysteine engineered fibronectin type iii domain binding molecules
CN110437145A (zh) * 2016-09-13 2019-11-12 上海翔锦生物科技有限公司 酪氨酸激酶抑制剂及其应用
CN107235897B (zh) * 2016-09-27 2019-08-16 上海翔锦生物科技有限公司 酪氨酸激酶抑制剂及其应用
US10597438B2 (en) 2016-12-14 2020-03-24 Janssen Biotech, Inc. PD-L1 binding fibronectin type III domains
EP3932432A1 (en) 2016-12-14 2022-01-05 Janssen Biotech, Inc. Cd8a-binding fibronectin type iii domains
WO2018111978A1 (en) 2016-12-14 2018-06-21 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
WO2018139527A1 (ja) 2017-01-26 2018-08-02 小野薬品工業株式会社 キノリン誘導体のエタンスルホン酸塩
JP6771594B2 (ja) 2017-02-15 2020-10-21 大鵬薬品工業株式会社 医薬組成物
EP3682882A4 (en) 2017-09-08 2021-06-02 Taiho Pharmaceutical Co., Ltd. ANTI-TUMOR AGENT AND ANTI-TUMOR POTENTIALIZER
WO2019074116A1 (ja) 2017-10-13 2019-04-18 小野薬品工業株式会社 Ａｘｌ阻害剤を有効成分として含む固形がん治療剤
CN115569137A (zh) 2018-06-15 2023-01-06 汉达癌症医药责任有限公司 激酶抑制剂的盐类及其组合物
BR112021014504A2 (pt) * 2019-01-25 2021-09-28 Exelixis, Inc. Compostos para o tratamento de transtornos dependentes de cinase
US12491255B2 (en) 2019-10-14 2025-12-09 Aro Biotherapeutics Company EPCAM binding fibronectin type III domains
CN119119240A (zh) 2019-10-14 2024-12-13 Aro生物疗法公司 结合cd71的纤维粘连蛋白iii型结构域
US11781138B2 (en) 2019-10-14 2023-10-10 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
CN115073367A (zh) * 2021-03-16 2022-09-20 南京科默生物医药有限公司 一种用作axl抑制剂的抗肿瘤化合物及其用途
IL307595A (en) 2021-04-14 2023-12-01 Aro Biotherapeutics Company FN3 RNA-silencing region conjugates and their uses
WO2022221505A2 (en) 2021-04-14 2022-10-20 Aro Biotherapeutics Company Cd71 binding fibronectin type iii domains
AU2024215796A1 (en) 2023-01-31 2025-05-15 Handa Oncology, Llc Improved cabozantinib compositions and methods of use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1353693B1 (en) * 2001-01-16 2005-03-16 Glaxo Group Limited Pharmaceutical combination containing a 4-quinazolineamine and paclitaxel, carboplatin or vinorelbine for the treatment of cancer
ES2436888T3 (es) * 2003-09-26 2014-01-07 Exelixis, Inc Moduladores c-Met y métodos de uso
ITRM20030475A1 (it) * 2003-10-15 2005-04-16 Sipa Societa Industrializzazione P Rogettazione E Impianto e metodo per il condizionamento termico di oggetti
UA96139C2 (uk) * 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
AU2006324477A1 (en) * 2005-12-15 2007-06-21 Medimmune Limited Combination of angiopoietin-2 antagonist and of VEGF-A, KDR and/or Flt1 antagonist for treating cancer
US20070213319A1 (en) * 2006-01-11 2007-09-13 Angion Biomedica Corporation Modulators of hepatocyte growth factor/c-Met activity
PL2101759T3 (pl) * 2006-12-14 2019-05-31 Exelixis Inc Sposoby stosowania inhibitorów MEK
EP2851091B1 (en) * 2007-04-13 2017-12-27 Dana-Farber Cancer Institute, Inc. Methods for treating cancer resistant to ERBB therapeutics
KR101523788B1 (ko) * 2007-05-17 2015-06-26 제넨테크, 인크. 뉴로필린 단편 및 뉴로필린-항체 복합체의 결정 구조
WO2009017838A2 (en) * 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
EP2190429B1 (en) * 2007-09-10 2016-04-20 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI478933B (zh) * 2011-01-28 2015-04-01 Konruns Pharmaceutical Co Ltd A quinoline compound containing a phosphorus substituent and a process for preparing the same, and a pharmaceutical composition containing the same and a use thereof
US9522902B2 (en) 2011-11-14 2016-12-20 Ignyta, Inc. Uracil derivatives as AXL and c-MET kinase inhibitors
TWI562989B (en) * 2011-11-14 2016-12-21 Ignyta Inc Uracil derivatives as axl and c-met kinase inhibitors
US9745283B2 (en) 2011-11-14 2017-08-29 Ignyta, Inc. Uracil derivatives as AXL and c-MET kinase inhibitors
US10017496B2 (en) 2011-11-14 2018-07-10 Ignyta, Inc. Uracil derivatives as AXL and c-MET kinase inhibitors

Also Published As

Publication number Publication date
BRPI0912582A2 (pt) 2015-07-28
EA201071268A1 (ru) 2011-06-30
JP2011519941A (ja) 2011-07-14
US20130150363A1 (en) 2013-06-13
UY31800A (es) 2009-11-10
WO2009137429A1 (en) 2009-11-12
ZA201007722B (en) 2011-08-31
CN102083824A (zh) 2011-06-01
EP2274304A1 (en) 2011-01-19
AU2009244453A1 (en) 2009-11-12
SG190623A1 (en) 2013-06-28
AU2009244453B2 (en) 2012-07-19
KR20110004462A (ko) 2011-01-13
EP2274304A4 (en) 2012-05-30
CL2009001063A1 (es) 2010-09-24
US20090274693A1 (en) 2009-11-05
CA2723699A1 (en) 2009-11-12
IL209057A0 (en) 2011-01-31
EA020779B1 (ru) 2015-01-30
PE20091832A1 (es) 2009-12-25
AR071631A1 (es) 2010-06-30
US20130142790A1 (en) 2013-06-06
MX2010012101A (es) 2010-11-30

Similar Documents

Publication Publication Date Title
TW201006829A (en) Method of treating cancer using a cMET and AXL inhibitor and an erbB inhibitor
KR101950044B1 (ko) Ａｋｔ 억제제 화합물 및 베무라페닙의 조합물, 및 사용 방법
JP5778735B2 (ja) Ｅｇｆｒ依存性疾患またはｅｇｆｒファミリーメンバーを標的とする薬剤に対して耐性を獲得した疾患を治療するためのピリミジン誘導体の使用
JP2020514356A (ja) Ｒｏｓ１キナーゼ阻害剤としての大環状化合物
KR20240014585A (ko) 악성 종양 치료용 제제 및 조성물
TWI594986B (zh) Antineoplastic agent effect enhancer
CN118785911A (zh) 用于治疗肿瘤的药物组合物
TW200522966A (en) Dosing schedule for a novel anticancer agent
JP2010534219A (ja) Ｅｇｆｒ依存性疾患またはｅｇｆｒファミリーメンバーを標的とする薬剤に対して耐性を獲得した疾患の処置のための、イミダゾキノリンの使用
JP2022027658A (ja) チロシンキナーゼ阻害剤と併用してｅｇｆ／ｅｇｆｒ経路を抑制する方法および組成物
WO2022072645A2 (en) Methods for treating cancer
Eskiler The interaction of PI3K inhibition with homologous recombination repair in triple negative breast cancer cells
TW202005651A (zh) 波齊替尼(poziotinib)與抗her1、her2或her4抗體之組合及使用彼之方法
KR20080046161A (ko) 비-소세포 폐암의 치료를 위한 스타우로스포린 유도체
US20140056910A1 (en) Therapeutic agent for cancer having reduced sensitivity to molecular target drug and pharmaceutical composition for enhancing sensitivity to molecular target drug
WO2024209717A1 (ja) 腫瘍治療用医薬組成物
US20230321087A1 (en) Fgfr inhibitor combination therapies
WO2022107864A1 (ja) 縮合ピリミジン化合物を有効成分とする脳移行性腫瘍治療剤
WO2024254298A1 (en) A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer
WO2024254266A1 (en) A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer
JP2024533432A (ja) ＰＩ３Ｋα阻害剤を含む医薬品の組合せ